Skip to content

The effects of endobronchial transexamic acid on controlling of pulmonary bleeding during bronchoschopy

Comparison of pulmonary bleeding control time with transexamic acid and adrenaline in patients with pulmonary hemorrhage

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014120220188N1
Enrollment
50
Registered
2015-03-04
Start date
2013-10-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary bleeding. Hemoptysis,Haemorrhage from other sites in respiratory passages, Haemorrhage from respiratory passages, unspecified

Interventions

Intervention 1: Interventional group: 500 mg tranexamic acid with 20ml saline were directly injected intrabronchial. Intervention 2: Control group: 1 mg adrenaline diluted with 20ml saline were direc
Treatment - Drugs
Interventional group: 500 mg tranexamic acid with 20ml saline were directly injected intrabronchial
Control group: 1 mg adrenaline diluted with 20ml saline were directly injected intrabronchial

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with pulmonary hemoptysis during brochoscopy Excusion criteria: Recent history of cerebral myocardial infarction; Recent history of cardiac arrhythmia; History of arterial embolization; History of clotting disorders; History of taking warfarin and antiplatelet medicines

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Bleeding time. Timepoint: During intervention. Method of measurement: Timer.

Secondary

MeasureTime frame
Side effects of medication. Timepoint: Three months after intervention. Method of measurement: Sign assessment.;Pulmonary hemorrhage. Timepoint: Three months after intervention. Method of measurement: Sign assessment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRozita Zarshenas

Kerman University of Medical Sciences

rozzarshenas@gmail.com+98 71 3732 1015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026